IL’s leadership in haemostasis market enables transition to direct business model

Instrumentation Laboratory (IL) recently announced that their Strategic Alliance Cross-Distribution agreement with Beckman Coulter (BCI) will terminate on June 22, 2012, after more than twenty successful years. From June 23, 2012, IL will initiate direct sales, service, support and marketing to end-user customers in the US and Canada, for their own haemostasis product line, including the HemosIL line of reagents, ACL TOP family of haemostasis testing systems, ACL ELITE/ELITE PRO analysers and other ACL systems.

The transition will allow IL to apply the same direct business model employed in their critical care business, for over fifty years, to their haemostasis product line. Closer proximity to the customer means IL can quickly respond to changing needs, continuously improve the quality of products and services, expedite innovation to haemostasis labs, and reduce complexity of operations. R&D and manufacturing for all of IL’s haemostasis analysers and reagents, along with the company’s world-class haemostasis expertise, reside at their headquarters in Massachusetts and New York, USA.

IL will honour all customer contracts, including end-user and group purchasing organisation agreements. All current pricing, terms and conditions will remain in effect through the term of any existing agreement.

Instrumentation Laboratory